The Discounted Cash Flow (DCF) valuation of Egetis Therapeutics AB (publ) (EGTX.ST) is (830.74) SEK. With the latest stock price at 6.27 SEK, the upside of Egetis Therapeutics AB (publ) based on DCF is -13349.5%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.0% - 7.3% | 6.2% |
| Long-term Growth Rate | 3.0% - 4.8% | 3.9% |
| Fair Price | (7,463.41) - (443.76) | (830.74) |
| Upside | -119133.7% - -7177.5% | -13349.5% |